Merck’s next-gen pneumococcal vaccine strides forward after two phase 3 wins

Merck & Co.’s next-generation pneumococcal vaccine has secured success in a pair of phase 3 trials, bringing the Big Pharma within touching distance of getting the first pneumococcal conjugate shot specifically designed for adults to market.